318 related articles for article (PubMed ID: 29051803)
1. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Gallogly MM; Lazarus HM; Cooper BW
Ther Adv Hematol; 2017 Sep; 8(9):245-261. PubMed ID: 29051803
[TBL] [Abstract][Full Text] [Related]
2. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
Gallogly MM; Lazarus HM
J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
Schlenk RF; Kayser S
Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
7. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Stone RM; Manley PW; Larson RA; Capdeville R
Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Sly N; Gaspar K
Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
Weisberg E; Sattler M; Manley PW; Griffin JD
Onco Targets Ther; 2018; 11():175-182. PubMed ID: 29343975
[TBL] [Abstract][Full Text] [Related]
11. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.
Abbas HA; Alfayez M; Kadia T; Ravandi-Kashani F; Daver N
Cancer Manag Res; 2019; 11():8817-8828. PubMed ID: 31632141
[No Abstract] [Full Text] [Related]
13. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
14. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Galinsky I; Coleman M; Fechter L
Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
[TBL] [Abstract][Full Text] [Related]
15. MDM2- and FLT3-inhibitors in the treatment of
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
[TBL] [Abstract][Full Text] [Related]
16. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
[TBL] [Abstract][Full Text] [Related]
17. Treatment practice and outcomes in
Chua CC; Grigg A; Singh J; Droogleever MP; Zhang L; Lim A; Fong CY; Ting SB; Schwarer A; Tiong IS; Wei AH
Leuk Lymphoma; 2020 Apr; 61(4):848-854. PubMed ID: 31752581
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Tvedt TH; Nepstad I; Bruserud Ø
Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
